Tosun, Nurcan CalimliGunduz, OzgurUlugol, Ahmet2024-06-122024-06-1220150300-95641435-1463https://doi.org/10.1007/s00702-014-1251-xhttps://hdl.handle.net/20.500.14551/18337Itch and pain are two irritating sensations sharing a lot in common. Considering the antinociceptive effects of blockade of endocannabinoid degrading enzymes in pain states, we attempted to reduce scratching behavior by endocannabinoid modulation, i.e. by inhibiting fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL), or cellular uptake of endocannabinoids. Scratching behavior was induced by intradermal injection of serotonin to Balb/c mice. URB597 (10 mg/kg, i.p.), a FAAH inhibitor, JZL184 (16 mg/kg, i.p.), a MAGL inhibitor, and AM404 (10 mg/kg, i.p.), an endocannabinoid transport inhibitor, were given to evaluate the effects of endocannabinoid modulation on scratching responses. Then, the CB1 receptor antagonist, AM251 (1 mg/kg, i.p.), and the CB2 receptor antagonist, SR144528 (1 mg/kg, i.p.), were administered to determine whether cannabinoid receptors mediate these effects. URB597 and JZL184, but not AM404, attenuated serotonin-induced scratches. The inhibitory effect of URB597 was reversed by SR144528, but cannabinoid receptor antagonists had no other effects on modulation by the inhibitors. We propose that augmenting the endocannabinoid tonus by inhibition of degradative enzymes, FAAH and MAGL, but not cellular uptake, may be a novel target for the development of antipruritic agents.en10.1007/s00702-014-1251-xinfo:eu-repo/semantics/closedAccessAM404EndocannabinoidsFAAHMAGLPruritusJZL184URB597Cannabinoid AgonistInflammatory PainNeuropathic PainSpinal-CordMiceReceptorsSystemPruritusTargetFaahArticle1223363367Q2WOS:0003500331000042-s2.0-8493988595324915981Q2